RxDoctor Payments Data

Larry Charlamb, MD

Cardiovascular Disease · Liverpool, NYNPI 1376541730

Payments from drug & device makers

$1,194in general payments, 2019–2025

Across 63 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$214
  • Johnson & Johnson$112
  • Amgen$97
  • Boston Scientific$73
  • Novartis$68
  • Biosense Webster, Inc.$65
  • plus $564 from 16 others

What the payments were for

  • Food & beverage$1,194100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,194 in reported general payments places this provider in the 40th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$99,524
Medicare patients
543
Services billed
1,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban219$298,112
XareltoRivaroxaban84$119,002
JardianceEmpagliflozin26$35,446
EntrestoSacubitril/Valsartan14$21,945
Repatha SureclickEvolocumab18$16,900
Metoprolol Succinate375$5,666
Atorvastatin Calcium314$3,238
Digoxin93$2,342
Rosuvastatin Calcium153$2,292
Losartan Potassium134$1,564
Ranolazine ErRanolazine15$1,447
Lisinopril169$1,378
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,306
Potassium Chloride58$1,234
Amlodipine Besylate211$1,229

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$45$298,112219 claims
Johnson & JohnsonXarelto$112$119,00284 claims
Boehringer IngelheimJardiance$63$35,44626 claims
NovartisEntresto$68$21,94514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Liverpool

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →